Prostate Cancer

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.

Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings.

Data from the GETUG-AFU 18 trial support high-dose radiation plus long-term androgen deprivation therapy as a standard of care in high-risk prostate cancer.

Four of 5 patients with prostate cancer and ctDNA positivity had disease progression following treatment with darolutamide plus androgen deprivation therapy in a phase 2 trial.

Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.

The overall incidence of bone fractures with prior EBRT to the bone in patients with metastatic castration-resistant prostate cancer remains low.

Additional education on tumor testing and PARP inhibitor therapy is warranted for patients with metastatic castration-resistant prostate cancer, according to Neal Shore, MD, FACS.

Findings support cabozantinib plus atezolizumab as a potential new treatment option for those with metastatic castration-resistant prostate cancer that has progressed on a novel hormonal therapy.

The FDA previously granted approval to frontline olaparib plus abiraterone/prednisone in May 2023 for BRCA1/2–, DDR–altered metastatic castration-resistant prostate cancer.

Darolutamide correlates with a marginally longer length of stay per hospitalization compared with placebo among those with metastatic hormone-sensitive prostate cancer.

While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.

Compared with surgery and radiation, focal therapy improves quality of life as well as decreases financial toxicity for patients with prostate cancer.

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Radiographic progression-free survival outcomes with olaparib plus abiraterone acetate and prednisone appear to be consistent with prior analyses of the phase 3 PROpel trial.

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.

Data from a phase 2 trial suggests that earlier use of abiraterone acetate/prednisone plus cabazitaxel may elicit clinical benefit in patients with metastatic castration-resistant prostate cancer.

Median radiographic progression-free survival appears to be higher in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 than those receiving androgen receptor pathway inhibitors.

Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.

Subgroup analyses in the phase 3 KEYNOTE-641 trial do not indicate an overall survival improvement with pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer.

Findings from the ENZA-p study provide evidence for enhanced anti-cancer effects with 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Findings from a meta-analysis highlight the effect of varying censorship criteria for the definition of surrogate end points in localized prostate cancer randomized clinical trials.

Over half of all patients with small cell neuroendocrine prostate cancer treated with BXCL701 and pembrolizumab were alive at 1 year in a phase 2 trial.

In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.

Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.

An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.